这项研究的目的是探讨癌症患者在姑息期的25-羟基维生素D(25-OHD)水平与季节的关系。性别,年龄,肿瘤类型,结肠切除术,和生存。为此,我们对“姑息-D”进行了事后分析,随机安慰剂对照,一项双盲试验,研究每天补充4000IU维生素D12周对姑息癌症治疗患者疼痛的影响.在筛查队列中(n=530),10%的患者25-OHD水平<25nmol/L,50%<50,84%<75nmol/L基线25-OHD在季节或肿瘤类型之间没有差异,并且与生存时间无关。在补充维生素D的维生素D缺乏患者(n=67),86%达到了足够的水平,即,>50nmol/L,12周后。补充女性的25-OHD增加幅度大于男性(53vs.37nmol/L,p=0.02),并且不受季节影响。在安慰剂组(n=83),在研究期间,对于在今年最后一个季度招募的患者,发现25-OHD水平下降.总之,姑息期的癌症患者在补充维生素D后,无论季节如何,25-OHD都有足够的增加,年龄,肿瘤类型,或者结肠切除术.
The purpose of this
study is to explore 25-hydroxyvitamin D (25-OHD) levels in patients with cancer in the palliative phase in relation to season, sex, age, tumor type, colectomy, and survival. To this end, we performed a post-hoc analysis of ‘Palliative-D’, a randomized placebo-controlled, double-blind
trial investigating the effect of daily supplementation with 4000 IU of vitamin D for 12 weeks on pain in patients in palliative cancer care. In the screening cohort (n = 530), 10% of patients had 25-OHD levels < 25 nmol/L, 50% < 50, and 84% < 75 nmol/L. Baseline 25-OHD did not differ between seasons or tumor type and was not correlated with survival time. In vitamin D deficient patients supplemented with vitamin D (n = 67), 86% reached sufficient levels, i.e., >50 nmol/L, after 12 weeks. An increase in 25-OHD was larger in supplemented women than in men (53 vs. 37 nmol/L, p = 0.02) and was not affected by season. In the placebo-group (n = 83), decreased levels of 25-OHD levels were noted during the
study period for patients recruited during the last quarter of the year. In conclusion, cancer patients in palliative phase have adequate increase in 25-OHD after vitamin D supplementation regardless of season, age, tumor type, or colectomy.